Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Licensing revenue	$ 0	$ 850
Operating expenses:
Research and development	55,969	42,342
General and administrative	16,870	15,133
Total operating expenses	72,839	57,475
Loss from operations	(72,839)	(56,625)
Interest income	6,350	7,250
Net loss	$ (66,489)	$ (49,375)
Net loss per share - basic and diluted (in dollars per share)	$ (0.42)	$ (0.36)
Basic and diluted weighted average shares outstanding (in shares)	157,695	137,384
Other comprehensive loss:
Net loss	$ (66,489)	$ (49,375)
Unrealized gain on marketable securities	70	173
Comprehensive loss	$ (66,419)	$ (49,202)